StreetInsider.com News Articles

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

Presentations will highlight Celea’s differentiated approach to advancing deupirfenidone for idiopathic pulmonary fibrosis (IPF), including details of the Phase 3 SURPASS-IPF trial design and key insights from a Phase 1 drug-drug interaction study with nintedanib

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, is pleased to note that its Founded Entity Celea Therapeutics (“Celea”) today announced that it will deliver two presentations showcasing its deupirfenidone (LYT-100) program at the upcoming European Respiratory Society (ERS) Congress,

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

Tue, 25 Aug 2026 07:05:00 -0400

Celea Therapeutics to present Phase 3 IPF trial data at ERS Congress

Tue, 25 Aug 2026 07:00:45 -0400

Celea Therapeutics, Inc. will present data from its deupirfenidone (LYT-100) program at the European Respiratory Society Congress in Barcelona, Spain, scheduled for September 5-9, 2026, according to a company press release.

The company will deliver two presentations. The first, on September 6, will detail the design and rationale for SURPASS-IPF, a global, randomized, double-blind Phase 3 trial comparing deupirfenidone 825 mg three times daily against pirfenidone 801 mg three times daily in approximately 1,100 adults with idiopathic pulmonary fibrosis (IPF). The primary endpoint is change from baseline in absolute forced vital capacity at Week 52. Celea describes SURPASS-IPF as the first